CAR-T is a type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.

DelveInsight’s, CAR-T Pipeline Insights, 2021,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Get free sample report: www.delveinsight.com/sample-request/car-t-pipeline-insight

Some of the CAR-T Companies:

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC.
  • Amgen, Inc.
  • Atara Biotherapeutics, Inc.
  • Aurora Biopharma, Inc.
  • Autolus Therapeutics PLC.
  • Bellicum Pharmaceuticals, Inc.
  • BioAtla LLC.
  • bluebird bio
  • Carina Biotech
  • CARsgen Therapeutics, Ltd.
  • CARTherics
  • Celgene
  • Cellectis
  • Celularity
  • Celyad SA
  • Creative Biolabs
  • DiaCarta, Inc.
  • Endocyte, Inc.
  • F1 Oncology, Inc.
  • Fate Therapeutics Inc.
  • Gilead
  • Humanigen, Inc.
  • Immune Therapeutics, Inc.
  • Intrexon, Corp.
  • Juno Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Lion TCR Pte Ltd.
  • MaxCyte, Inc.
  • Mesoblast, Ltd.
  • Minerva Biotechnologies Corp.
  • Mustang Bio, Inc.
  • Novartis AG
  • Oxford BioMedica PLC.
  • PeproMene Bio Inc.
  • Pfizer, Inc.
  • Posedia Therapeutics Inc.
  • Precision Biosciences, Inc.
  • ProMab Biotechnologies Inc.
  • Servier Oncology
  • Sorrento Therapeutics, Inc.
  • TC Biopharm Ltd.
  • Tessa Therapeutics Pte Ltd.
  • TILT Biotherapeutics Ltd.
  • Tmunity Therapeutics Inc.
  • TrakCel Ltd.
  • Xyphos
  • ZIOPHARM Oncology, Inc.
  • And Many Others

Get free sample report: www.delveinsight.com/sample-request/car-t-pipeline-insight

Some of the CAR-T Therapies:

  • LCAR-B38M CAR-T Cell
  •  Anti-CEA CAR-T cells
  •  CD30.CAR-T
  •  AUTO CAR T cell therapy
  •  Defibrotide
  •  MB-CART2019.1 Dose level 1
  •  CAR-T
  •  CD19/22 CART
  •  JNJ-68284528
  •  CD123 CAR-T cells
  •  CD19 CAR-T cells
  •  BCMA CAR-T cells
  •  CEA CAR-T cells
  •  CAR-T cell immunotherapy
  •  Autologous CAR-T cells
  •  Second generation CAR-T cells
  •  CAR-T/TCR-T cells immunotherapy
  •  Allogeneic hematological stem cell transplantation
  •  Humanized CD19 CAR-T cells
  •  CD19 CART
  •  MB-CART20.1
  •  MB-CART19.1
  •  IM19 CAR-T Cells
  •  CLDN6 CAR-T
  •  Autologous CD19-targeting CAR T cells
  •  P-BCMA-101 CAR-T cells
  •  MLM-CAR44.1 T-cells, cyclophosphamide and fludarabine from -5 to -3
  •  CART-19/22
  •  Anakinra
  •  Anti-MUC1 CAR-T cells
  •  CAR T-cell therapy
  •  CAR T cells
  •  CART-19
  •  CAR-CD19 T Cells
  •  CAR-BCMA T Cells
  •  LCAR-B38M CAR-T cell injection
  •  AUTO1
  •  AUTO3
  • And Many Others

Get free sample report: www.delveinsight.com/sample-request/car-t-pipeline-insight

Table of Contents:

Introduction

Executive Summary

CAR-T: Overview

Pipeline Therapeutics

Therapeutic Assessment

CAR-T – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • CAR-T companies’ collaborations, Licensing, Acquisition -Deal Value Trends

CAR-T Collaboration Deals

Late Stage Products (Phase II)

JNJ-68284528: Janssen Research & Development, LLC

Mid Stage Products (Phase II)

LCAR-B38M CAR-T Cell: Nanjing Legend Biotech Co.

CD30.CAR-T: Tessa Therapeutics

Early Stage Products (Phase I)

IM21 CAR-T cells: Beijing Immunochina Medical Science & Technology Co., Ltd.

Pre-clinical and Discovery Stage Products

Research programme: CAR-T cell therapy – Endocyte/Seattle Childrens Research Institute

Research programme: chimeric antigen receptor T cell therapies – CRISPR Therapeutics

Inactive Products

Comparative Analysis

CAR-T- Market Drivers and Barriers

Appendix

Other Links:

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact us
Ankit Nigam
[email protected]
+91-9650213330
www.delveinsight.com/

Connect With Us at:
LinkedIn
 | Facebook | Twitter

Get Free Sample Copy of Report at: www.delveinsight.com/sample-request/car-t-pipeline-insight

clarkcountyblog.com/





Source link